Crinetics Pharmaceuticals/ US22663K1079 /
| 6/10/2024 9:59:59 PM | Chg. +0.40 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 45.06USD | +0.90% | 16,592 Turnover: 739,516.61 |
-Bid Size: - | -Ask Size: - | 45.06 | 43.80 |
GlobeNewswire
6/3
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Ora...
GlobeNewswire
6/3
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label...
GlobeNewswire
5/30
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...
GlobeNewswire
5/22
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
GlobeNewswire
5/10
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5/9
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/8
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Develop...
GlobeNewswire
5/2
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
GlobeNewswire
4/11
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(...
GlobeNewswire
3/19
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase...
GlobeNewswire
3/12
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of ...
GlobeNewswire
3/11
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
GlobeNewswire
2/28
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
2/28
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
GlobeNewswire
2/14
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February ...
GlobeNewswire
2/12
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c...
GlobeNewswire
1/10
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)...
GlobeNewswire
1/3
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
12/18/2023
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine f...
GlobeNewswire
12/11/2023
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c...
GlobeNewswire
11/10/2023
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c...
GlobeNewswire
11/7/2023
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
10/10/2023
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
